<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05016908</url>
  </required_header>
  <id_info>
    <org_study_id>2019P001504</org_study_id>
    <nct_id>NCT05016908</nct_id>
  </id_info>
  <brief_title>Extracellular RNA Biomarkers of Duchenne Muscular Dystrophy</brief_title>
  <official_title>Extracellular RNA Biomarkers of Duchenne Muscular Dystrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boston Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Current methods of measuring the response to new treatments for muscular dystrophies involve&#xD;
      the examination of small pieces of muscle tissue called biopsies. The investigators are&#xD;
      interested in finding less invasive methods that reduce the need for muscle biopsies. The&#xD;
      purpose of this research is to learn about the possibility of detecting and measuring the&#xD;
      activity and severity of muscular dystrophies by examining a urine sample and a blood sample.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 30, 2019</start_date>
  <completion_date type="Anticipated">November 2023</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Extracellular RNA in biofluids</measure>
    <time_frame>4 years</time_frame>
    <description>The extracellular RNA biomarkers in the muscular dystrophy groups will be evaluated and compared with the extracellular RNA content in control groups. Statistical analysis will be used to evaluate the sensitivity and specificity of these markers as measurements of disease activity and severity.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Duchenne Muscular Dystrophy</condition>
  <arm_group>
    <arm_group_label>Biofluid collection</arm_group_label>
    <description>Eligible volunteers will be asked to provide a single urine sample and undergo a single blood draw.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Males ages 5 years and older with Duchenne muscular dystrophy (DMD) or Becker muscular&#xD;
        dystrophy (BMD). In addition, male and female family members without known muscular&#xD;
        dystrophy ages 18 and older also are invited to participate.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects with DMD or BMD based on genetic testing. Control subjects are unknown to&#xD;
             have any other muscular dystrophy by history and may have had no genetic testing.&#xD;
&#xD;
          -  Able to provide informed consent or assent for participation in the study.&#xD;
&#xD;
          -  Demographic characteristics for biofluid collection: Males age 5 years and older with&#xD;
             DMD or BMD; males and females ages 18 years and older without muscular dystrophy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Medical history of any of the following: State of immunosuppression; coagulopathy;&#xD;
             pre-existing liver or kidney disease; documented HIV positive; documented hepatitis B&#xD;
             and/or C positive.&#xD;
&#xD;
          -  Use of anti-platelet drugs within 7 days prior to blood draw; use of anticoagulants&#xD;
             within 60 days prior to blood draw.&#xD;
&#xD;
          -  Inability or unwillingness of the subject to give written informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Thurman M. Wheeler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Brigham McKee</last_name>
    <phone>617-726-7506</phone>
    <email>bmckee2@mgh.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Parker Conquest</last_name>
    <phone>617-726-7506</phone>
    <email>econquest@mgh.harvard.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alyssa Rohan</last_name>
      <phone>617-919-1806</phone>
      <email>alyssa.rohan@childrens.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Abigail Druffner</last_name>
      <phone>617-919-1806</phone>
      <email>abigail.druffner@childrens.harvard.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Basil T. Darras, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02129</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brigham McKee</last_name>
      <phone>617-726-7506</phone>
      <email>bmckee2@mgh.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Parker Conquest</last_name>
      <phone>617-726-7506</phone>
      <email>econquest@mgh.harvard.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Thurman M. Wheeler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Antoury L, Hu N, Balaj L, Das S, Georghiou S, Darras B, Clark T, Breakefield XO, Wheeler TM. Analysis of extracellular mRNA in human urine reveals splice variant biomarkers of muscular dystrophies. Nat Commun. 2018 Sep 25;9(1):3906. doi: 10.1038/s41467-018-06206-0.</citation>
    <PMID>30254196</PMID>
  </reference>
  <reference>
    <citation>Antoury L, Hu N, Darras B, Wheeler TM. Urine mRNA to identify a novel pseudoexon causing dystrophinopathy. Ann Clin Transl Neurol. 2019 May 17;6(6):1106-1112. doi: 10.1002/acn3.777. eCollection 2019 Jun.</citation>
    <PMID>31211175</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 16, 2021</study_first_submitted>
  <study_first_submitted_qc>August 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 23, 2021</study_first_posted>
  <last_update_submitted>August 20, 2021</last_update_submitted>
  <last_update_submitted_qc>August 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Thurman Wheeler, M.D</investigator_full_name>
    <investigator_title>Physician Scientist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

